Ticagrelor Removal From Human Blood

Abstract

Visual Abstract

Kardioanästhesie: Monitoring der Gerinnung und Gerinnungstherapie

“…Aktuelle klinische Untersuchungen beschäftigen sich mit dem Einsatz von Zytokinfiltern an der Herz-Lungen-Maschine. Eine In-vitro-Studie konnte zeigen, dass Ticagrelor durch einen Zytokinfilter aus dem Blut herausgefiltert werden kann [25]. Inwieweit der Einsatz eines Zytokinfilters das Blutungsrisiko bei entsprechenden Patienten an der Herz-Lungen-Maschine reduziert, wird aktuell untersucht.…”

New alternative to antidotes for novel oral anticoagulants and ticagrelor in the case of severe bleeding

“…New alternative to antidotes for novel oral anticoagulants and ticagrelor in the case of severe bleeding Patrick M. Honore * , Christina David, Rachid Attou, Sebastien Redant, Andrea Gallerani and David De Bels Kuramatsu et al reviewed current therapies for reversal of new oral anticoagulants (NOACs) and anti-platelet agents in patients with acute intracerebral hemorrhage [1]. In their comments on "Unspecific reversal approaches," we believe that the authors have overlooked another new way to reverse this anticoagulation, especially with NOACs such as rivaroxaban and dabigatran and the new antiplatelet drug, ticagrelor [2]. In the case of severe intoxication with these NOACs or new anti-platelet agents, there is a promising new therapy based upon the use of the CytoSorb device [2].…”

“…In their comments on "Unspecific reversal approaches," we believe that the authors have overlooked another new way to reverse this anticoagulation, especially with NOACs such as rivaroxaban and dabigatran and the new antiplatelet drug, ticagrelor [2]. In the case of severe intoxication with these NOACs or new anti-platelet agents, there is a promising new therapy based upon the use of the CytoSorb device [2]. CytoSorb can very efficiently remove NOACS and anti-platelets agents in order to restore normal coagulation and platelet function and to stop bleeding wherever it is occurring [2].…”

“…In the case of severe intoxication with these NOACs or new anti-platelet agents, there is a promising new therapy based upon the use of the CytoSorb device [2]. CytoSorb can very efficiently remove NOACS and anti-platelets agents in order to restore normal coagulation and platelet function and to stop bleeding wherever it is occurring [2]. In their study, Angheloiu et al were able to remove 99% of ticagrelor from human blood in less than 4 h when using CytoSorb [2].…”

“…CytoSorb can very efficiently remove NOACS and anti-platelets agents in order to restore normal coagulation and platelet function and to stop bleeding wherever it is occurring [2]. In their study, Angheloiu et al were able to remove 99% of ticagrelor from human blood in less than 4 h when using CytoSorb [2]. They concluded that Cyto-Sorb can remove representative molecules from two classes of agents-antiplatelet and anticoagulant-and in the future could complement the use of a newly developed specific monoclonal antibody reversal agent for ticagrelor, which is still in the pre-clinical phase and not yet available at the bedside [3].…”